Measuring dengue illness intensity: Development and content validity of the dengue virus daily diary (DENV-DD).
Clinical outcome assessment (COA)
Cognitive debriefing
Concept elicitation
Dengue
Dengue human infection model (DHIM)
Observer-reported outcome (ObsRO)
Patient-reported outcome (PRO)
Qualitative
Quantitative
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
23 08 2023
23 08 2023
Historique:
received:
10
03
2023
accepted:
01
08
2023
medline:
24
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Dengue is the most prevalent arboviral infection causing an estimated 50-60 million cases of febrile illness globally per year, exacting considerable disease burden. Few instruments exist to assess the patient illness experience, with most based on healthcare provider assessment, lacking standardization in timepoints and symptom assessment. This study aimed to evaluate the content validity of the novel 'Dengue Virus Daily Diary (DENV-DD)', designed to measure symptom intensity and disease burden within outpatient infant to adult populations. The Dengue Illness Index Report Card was used as a foundation to create the DENV-DD, consisting of patient- and observer-reported outcome (PRO/ObsRO) instruments. In two South American dengue-endemic communities, qualitative combined concept elicitation and cognitive debriefing interviews were conducted among individuals and caregivers of children with symptomatic laboratory-confirmed dengue. Interviews were conducted across two rounds allowing DENV-DD modifications. A small-scale quantitative assessment of the DENV-DD was also conducted with data from an independent Dengue Human Infection Model (DHIM) to generate early evidence of feasibility of DENV-DD completion, instrument performance and insight into the sign/symptom trajectory over the course of illness. Forty-eight participants were interviewed (20 adults, 20 older children/adolescents with their caregivers, 8 caregivers of younger children). A wide spectrum of signs/symptoms lasting 3-15 days were reported with fever, headache, body ache/pain, loss of appetite, and body weakness each reported by > 70% participants. DENV-DD instructions, items and response scales were understood, and items were considered relevant across ages. DHIM data supported feasibility of DENV-DD completion. Findings demonstrate content validity of the DENV-DD (PRO/ObsRO instruments) in dengue-endemic populations. Psychometric and cultural validity studies are ongoing to support use of the DENV-DD in clinical studies. Dengue is the most common viral infection transmitted to humans by mosquitos, and affects an estimated 50–60 million individuals globally per year. However, there are few resources for understanding and capturing the patient experience of dengue throughout illness. Most research studies are based on healthcare provider assessment, which lack consistency in terms of assessment time points and the signs/symptoms assessed. The ‘Dengue Illness Index Report Card (DII-RC)’ was used as a foundation to create the new ‘Dengue Virus Daily Diary (DENV-DD)’ to better capture the patient experience of symptom intensity and dengue disease burden for the duration of illness. Forty-eight individuals and caregivers of younger children from Peru and Ecuador who recently had symptomatic dengue were interviewed to understand the patient experience over the time of illness and to test whether the DENV-DD is understood by patients and caregivers and includes all relevant and important signs/symptoms and health-related quality of life impacts. Nine individuals with active dengue infection also completed the DENV-DD daily for 28-days as part of a clinical study. We found that > 70% of patients experienced fever, headache, body ache/pain, loss of appetite and body weakness. The DENV-DD instructions, questions and response option(s) were well understood, feasible to complete and the concepts assessed by the DENV-DD were relevant to the dengue experience. Our study adds to the understanding of the dengue illness experience and supports the DENV-DD for use in future dengue studies as an assessment of signs/symptoms throughout the duration of illness.
Sections du résumé
BACKGROUND
Dengue is the most prevalent arboviral infection causing an estimated 50-60 million cases of febrile illness globally per year, exacting considerable disease burden. Few instruments exist to assess the patient illness experience, with most based on healthcare provider assessment, lacking standardization in timepoints and symptom assessment. This study aimed to evaluate the content validity of the novel 'Dengue Virus Daily Diary (DENV-DD)', designed to measure symptom intensity and disease burden within outpatient infant to adult populations.
METHODS
The Dengue Illness Index Report Card was used as a foundation to create the DENV-DD, consisting of patient- and observer-reported outcome (PRO/ObsRO) instruments. In two South American dengue-endemic communities, qualitative combined concept elicitation and cognitive debriefing interviews were conducted among individuals and caregivers of children with symptomatic laboratory-confirmed dengue. Interviews were conducted across two rounds allowing DENV-DD modifications. A small-scale quantitative assessment of the DENV-DD was also conducted with data from an independent Dengue Human Infection Model (DHIM) to generate early evidence of feasibility of DENV-DD completion, instrument performance and insight into the sign/symptom trajectory over the course of illness.
RESULTS
Forty-eight participants were interviewed (20 adults, 20 older children/adolescents with their caregivers, 8 caregivers of younger children). A wide spectrum of signs/symptoms lasting 3-15 days were reported with fever, headache, body ache/pain, loss of appetite, and body weakness each reported by > 70% participants. DENV-DD instructions, items and response scales were understood, and items were considered relevant across ages. DHIM data supported feasibility of DENV-DD completion.
CONCLUSIONS
Findings demonstrate content validity of the DENV-DD (PRO/ObsRO instruments) in dengue-endemic populations. Psychometric and cultural validity studies are ongoing to support use of the DENV-DD in clinical studies.
Dengue is the most common viral infection transmitted to humans by mosquitos, and affects an estimated 50–60 million individuals globally per year. However, there are few resources for understanding and capturing the patient experience of dengue throughout illness. Most research studies are based on healthcare provider assessment, which lack consistency in terms of assessment time points and the signs/symptoms assessed. The ‘Dengue Illness Index Report Card (DII-RC)’ was used as a foundation to create the new ‘Dengue Virus Daily Diary (DENV-DD)’ to better capture the patient experience of symptom intensity and dengue disease burden for the duration of illness. Forty-eight individuals and caregivers of younger children from Peru and Ecuador who recently had symptomatic dengue were interviewed to understand the patient experience over the time of illness and to test whether the DENV-DD is understood by patients and caregivers and includes all relevant and important signs/symptoms and health-related quality of life impacts. Nine individuals with active dengue infection also completed the DENV-DD daily for 28-days as part of a clinical study. We found that > 70% of patients experienced fever, headache, body ache/pain, loss of appetite and body weakness. The DENV-DD instructions, questions and response option(s) were well understood, feasible to complete and the concepts assessed by the DENV-DD were relevant to the dengue experience. Our study adds to the understanding of the dengue illness experience and supports the DENV-DD for use in future dengue studies as an assessment of signs/symptoms throughout the duration of illness.
Autres résumés
Type: plain-language-summary
(eng)
Dengue is the most common viral infection transmitted to humans by mosquitos, and affects an estimated 50–60 million individuals globally per year. However, there are few resources for understanding and capturing the patient experience of dengue throughout illness. Most research studies are based on healthcare provider assessment, which lack consistency in terms of assessment time points and the signs/symptoms assessed. The ‘Dengue Illness Index Report Card (DII-RC)’ was used as a foundation to create the new ‘Dengue Virus Daily Diary (DENV-DD)’ to better capture the patient experience of symptom intensity and dengue disease burden for the duration of illness. Forty-eight individuals and caregivers of younger children from Peru and Ecuador who recently had symptomatic dengue were interviewed to understand the patient experience over the time of illness and to test whether the DENV-DD is understood by patients and caregivers and includes all relevant and important signs/symptoms and health-related quality of life impacts. Nine individuals with active dengue infection also completed the DENV-DD daily for 28-days as part of a clinical study. We found that > 70% of patients experienced fever, headache, body ache/pain, loss of appetite and body weakness. The DENV-DD instructions, questions and response option(s) were well understood, feasible to complete and the concepts assessed by the DENV-DD were relevant to the dengue experience. Our study adds to the understanding of the dengue illness experience and supports the DENV-DD for use in future dengue studies as an assessment of signs/symptoms throughout the duration of illness.
Identifiants
pubmed: 37610665
doi: 10.1186/s41687-023-00624-5
pii: 10.1186/s41687-023-00624-5
pmc: PMC10447358
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Subventions
Organisme : NIAID NIH HHS
ID : P01 AI098670
Pays : United States
Informations de copyright
© 2023. International Society for Quality of Life Research (ISOQOL).
Références
World Health Organisation (2017) Dengue vaccine: WHO position paper, July 2016–recommendations. Vaccine 35(9):1200–1201
doi: 10.1016/j.vaccine.2016.10.070
World Health Organisation (2022) Dengue and severe dengue
World Health Organisation (2018) Dengue vaccine: WHO position paper, September 2018. Wkly Epidemiol Rec 93(36):457–476
Cattarino L et al (2020) Mapping global variation in dengue transmission intensity. Sci Transl Med 12(528):eaax4144
doi: 10.1126/scitranslmed.aax4144
pubmed: 31996463
Toan NT et al (2015) Dengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting. Trop Med Int Health 20(7):840–863
doi: 10.1111/tmi.12498
pubmed: 25753454
Institute for Health Metrics and Evaluation. Dengue — Level 3 cause. 2019 [cited 25th November 2022 25th November 2022]. https://www.healthdata.org/results/gbd_summaries/2019/dengue-level-3-cause
Sabin AB (1952) Research on dengue during World War II. Am J Trop Med Hyg 1(1):30–50
doi: 10.4269/ajtmh.1952.1.30
pubmed: 14903434
Prompetchara E et al (2019) Dengue vaccine: global development update. Asian Pac J Allergy Immunol 10(3):178–185
Cassetti MC, Thomas SJ (2014) Dengue human infection model: introduction. J Infect Dis 209(suppl_2):S37–S39
doi: 10.1093/infdis/jiu061
pubmed: 24872393
pmcid: 4048991
World Health Organisation (2009) Dengue: guidelines for diagnosis, treatment, prevention and control
Biswal S et al (2019) Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381(21):2009–2019
doi: 10.1056/NEJMoa1903869
pubmed: 31693803
Capeding MR et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384(9951):1358–1365
doi: 10.1016/S0140-6736(14)61060-6
pubmed: 25018116
Thomas SJ et al (2018) Dengue illness index—a tool to characterize the subjective dengue illness experience. PLoS Negl Trop Dis 12(10):e0006593
doi: 10.1371/journal.pntd.0006593
pubmed: 30286086
pmcid: 6171819
US Food & Drug Administration (2018) Patient-focused drug development guidance: select, develop or modify fit-for-purpose clinical outcome assessments
US Food & Drug Administration (2018) Patient-focused drug development guidance: methods to identify what is important to patients
US Food & Drug Administration (2018) Patient-focused drug development guidance: collecting comprehensive and representative input. guidance for industry
Matza LS et al (2013) Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health 16(4):461–479
doi: 10.1016/j.jval.2013.04.004
pubmed: 23796280
Acquadro C et al (2018) Emerging good practices for translatability assessment (TA) of patient-reported outcome (PRO) measures. J Patient-Reported Outcomes 2(1):8
doi: 10.1186/s41687-018-0035-8
Saretsky T et al (2019) PIN96 development of patient-reported outcome (PRO) and observer-reported outcome (ObsRO) measures for assessment of symptom intensity in dengue illness. Value Health 22:S210
doi: 10.1016/j.jval.2019.04.966
Hasan MM et al (2022) Concurrent epidemics of dengue and COVID-19 in Peru: which way forward? Lancet Reg Health Am 12:100277
pubmed: 36776431
pmcid: 9903762
Stewart-Ibarra AM et al (2018) The burden of dengue fever and chikungunya in southern coastal Ecuador: epidemiology, clinical presentation, and phylogenetics from the first two years of a prospective study. Am J Trop Med Hyg 98(5):1444–1459
doi: 10.4269/ajtmh.17-0762
pubmed: 29512482
pmcid: 5953373
Lippi CA et al (2021) Exploring the utility of social-ecological and entomological risk factors for dengue infection as surveillance indicators in the dengue hyper-endemic city of Machala, Ecuador. PLoS Negl Trop Dis 15(3):e0009257
doi: 10.1371/journal.pntd.0009257
pubmed: 33740003
pmcid: 8011822
Stoddard ST et al (2013) House-to-house human movement drives dengue virus transmission. Proc Natl Acad Sci U S A 110(3):994–999
doi: 10.1073/pnas.1213349110
pubmed: 23277539
Morrison AC et al (2010) Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis 4(5):e670
doi: 10.1371/journal.pntd.0000670
pubmed: 20454609
pmcid: 2864256
Turner-Bowker DM et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839–842
doi: 10.1016/j.jval.2017.11.014
pubmed: 30005756
Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation and variability. Field Methods 18(1):59–82
doi: 10.1177/1525822X05279903
Eccles DW, Arsal G (2017) The think aloud method: what is it and how do I use it? Qual Res Sport Exerc Health 9(4):514–531
doi: 10.1080/2159676X.2017.1331501
GmbH, A.t.S.S.D (2017) ATLAS.ti 8 Windows. [8.0]
Marks M et al (2022) Dengue virus daily diary (DENV-DD)—a new patient-reported outcome (PRO) tool measuring dengue symptom intensity: Findings from a DEN-3 human challenge study. American Society for Tropical Medicine and Hygiene
Waickman AT et al (2022) Virologic, clinical, and immunological characteristics of a dengue virus 3 human challenge model. medRxiv
Elson WH et al (2020) Measuring health related quality of life for dengue patients in Iquitos, Peru. PLoS Negl Trop Dis 14(7):e0008477
doi: 10.1371/journal.pntd.0008477
pubmed: 32722709
pmcid: 7413550
Elson WH et al (2020) Heterogeneity of dengue illness in community-based prospective study, Iquitos, Peru. Emerg Infect Dis 26(9):2077
doi: 10.3201/eid2609.191472
pubmed: 32818402
pmcid: 7454099
Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11(3):480–496
doi: 10.1128/CMR.11.3.480
pubmed: 9665979
pmcid: 88892
Endy TP (2014) Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol 5:183
doi: 10.3389/fimmu.2014.00183
pubmed: 24795725
pmcid: 4006038
US Food & Drug Administration (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims
Tapia-Conyer R, Betancourt-Cravioto M, Méndez-Galván J (2012) Dengue: an escalating public health problem in Latin America. Paediatr Int Child Health 32(s1):14–17
doi: 10.1179/2046904712Z.00000000046
pubmed: 22668444
pmcid: 3381443
Torres R JR, Torres V CG (2002) Dengue in Latin America-a unique situation
San Martín JL et al (2010) The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 82(1):128–135
doi: 10.4269/ajtmh.2010.09-0346
pubmed: 20065008
pmcid: 2803522